Germline pathogenic variants in succinate dehydrogenase genes: implications from a single-institution study
Endocrine Oncology · 01.01.2026 · 6 (1)
DOI: 10.1530/eo-25-0113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 23.10.2026. Verfasst von Sanjana S Awasty und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Metabolism , Columbus, USA. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Germline pathogenic variants (PVs) in the succinate dehydrogenase (SDHx) genes are associated with inherited pheochromocytoma and paraganglioma (PPGL). Because of the high incidence of germline PVs, genetic testing is recommended for all cases of PPGL; relatives may, thus, be found through cascade testing. PPGL-associated genes are also included on cancer genetics panels, which may lead to variant identification related to other tumors. After PV detection, screening recommendations entail biochemical/radiologic testing and frequent surveillance.
Objective
The aim of this study was to assess the consequences and impact of these approaches in a cohort of individuals with germline PVs in the SDHx genes.
Design
Natural history study.
Setting
A single academic medical center. Patients or other participants A total of 156 patients with SDHx PVs were identified and included over a period of 10 years.
Interventions
None. Main outcome measures We report the distribution of PVs, rationale for genetic screening, tumor incidence, and second genetic variants.
Results
Of 156 patients with variants in the SDHx genes, PVs in SDHB were the most common. In probands tested for non-PPGL tumors, SDHA PVs were the most common, whereas SDHD cases were never detected in this manner. We also identified individuals with variants in a second cancer-associated gene. For individuals not found to have a tumor at initial presentation, the rate of tumor development was <5%.
Conclusion
SDHx PVs may be more common than expected, and there are gene-specific patterns of ascertainment. Future research is needed to evaluate the role of modifier variants on tumor risk. Reconsideration of surveillance guidelines may be appropriate given the low frequency of new lesions in tumor-free carriers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes, and Metabolism , Columbus, USA.
- Division of Human Genetics, The Ohio State University Wexner Medical Center , Columbus, OH, USA.
ORCID-Profile: Pamela L Brock, Lawrence S Kirschner
Zitieren
APA
Awasty, S. S., Fisher, C., Brock, P. L., & Kirschner, L. S. (2026). Germline pathogenic variants in succinate dehydrogenase genes: implications from a single-institution study. Endocrine Oncology, 6(1). https://doi.org/10.1530/eo-25-0113
Vancouver
Awasty SS, Fisher C, Brock PL, Kirschner LS. Germline pathogenic variants in succinate dehydrogenase genes: implications from a single-institution study. Endocrine Oncology. 2026;6(1). doi:10.1530/eo-25-0113
BibTeX
@article{Awasty2026,
author = {Awasty, Sanjana S and Fisher, Carly and Brock, Pamela L and Kirschner, Lawrence S},
title = {Germline pathogenic variants in succinate dehydrogenase genes: implications from a single-institution study},
journal = {Endocrine Oncology},
year = {2026},
volume = {6},
number = {1},
doi = {10.1530/eo-25-0113}
}
EUVIMED